Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at
Wall Stre
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA) [Yahoo! Finance]
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $56.00 to $63.00. They now have a "buy" rating on the stock.
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $45.00 price target on the stock.
Oruka Therapeutics GAAP EPS of -$0.55 beats by $0.01 [Seeking Alpha]